Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 11/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.41 |
| ▸ | CDK9 | P50750 | 9/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836411 | 1.00 | CDC7 (0.41) | CDC7CDK2CCNT1CDK9CCNA2 | |
| SCHEMBL29836494 | 0.90 | CCNT1 (0.41) | CDC7CDK2CCNT1CDK9CCNA2 | |
| SCHEMBL21591776 | 0.90 | CCNT1 (0.41) | CDC7CDK2CCNT1CDK9CCNA2 | |
| SCHEMBL21591781 | 0.87 | CLK4 (0.50) | CDC7CDK2CDK9PRKACAGSK3B | |
| SCHEMBL29836408 | 0.87 | CLK4 (0.50) | CDC7CDK2CDK9PRKACAGSK3B | |
| SCHEMBL21591764 | 0.86 | CYP1A2 (0.43) | CDC7CDK2CDK9CDK5PRKACA | |
| SCHEMBL29836349 | 0.86 | CYP1A2 (0.43) | CDC7CDK2CDK9CDK5PRKACA | |
| SCHEMBL23762196 | 0.85 | CDC7 (0.38) | CDC7CDK2CDK9CDK5PRKACA | |
| SCHEMBL21591763 | 0.84 | CDC7 (0.35) | CDC7CDK2CDK9CDK5PRKACA | |
| SCHEMBL29836525 | 0.84 | CDC7 (0.35) | CDC7CDK2CDK9CDK5PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | claimed |
| EP-3807273-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | claimed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CDC7 529/4885CDK2 730/4885CCNT1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.